CRDF

+ Watchlist + Portfolio

Cardiff Oncology, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.90
52-Week Range: $0.76 – $3.31
Market Cap: $70.69M
P/E (TTM): —
EPS (TTM): -0.61
Dividend Yield: —

Advanced Metrics

Price/Book: 2.35
PEG Ratio: —
Return on Equity: -94.08%
Return on Assets: -46.73%
Gross Margin: 0.00%
Operating Margin: -9245.19%
Profit Margin: 0.00%
Current Ratio: 3.30
Debt/Equity: 0.02
Total Debt: $457.00K
Free Cash Flow: $-24.30M
Revenue Growth: -14.10%
Earnings Growth: —
Enterprise Value: $36.63M

CRDF Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$386.00K	$488.00K	$683.00K	$593.00K
Research & Development	$27.11M	$32.86M	$36.85M	$35.33M
Selling, General & Admin	$13.18M	$13.04M	$12.48M	$14.22M
Operating Expenses	$40.29M	$45.90M	$49.33M	$49.55M
Operating Income	-$39.90M	-$45.41M	-$48.65M	-$48.96M
EBITDA	-$39.67M	-$45.01M	-$47.71M	-$48.06M
Pretax Income	-$38.70M	-$41.44M	-$45.43M	-$45.85M
Net Income	-$38.70M	-$41.44M	-$45.43M	-$45.85M
Diluted EPS	-0.89	-0.93	-0.95	-0.69
Diluted Shares	43.60M	44.68M	47.65M	66.84M

CRDF Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$16.35M	$21.66M	$51.47M	$17.47M
Receivables	$771.00K	$288.00K	$773.00K	$182.00K
Current Assets	$111.28M	$77.41M	$95.05M	$60.13M
Total Assets	$116.19M	$81.64M	$97.19M	$61.88M
Current Liabilities	$7.81M	$10.44M	$13.43M	$16.39M
Total Debt	$2.71M	$2.15M	$1.52M	$832.00K
Total Liabilities	$9.85M	$11.90M	$14.24M	$16.50M
Retained Earnings	-$298.10M	-$339.54M	-$384.18M	-$430.03M
Shareholders' Equity	$106.34M	$69.74M	$82.95M	$45.39M
Working Capital	$103.48M	$66.97M	$81.63M	$43.73M

CRDF Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$33.82M	-$30.89M	-$37.69M	-$37.92M
Capital Expenditure	-$1.01M	-$582.00K	-$80.00K	-$44.00K
Free Cash Flow	-$34.83M	-$31.47M	-$37.77M	-$37.97M
Depreciation & Amortisation	$236.00K	$398.00K	$943.00K	$904.00K
Stock-Based Compensation	$4.26M	$4.51M	$4.76M	$5.69M
Investing Cash Flow	$38.15M	$36.20M	$13.73M	$1.34M
Financing Cash Flow	$75.00K	$0.00	$53.78M	$2.58M
Net Change in Cash	$4.40M	$5.31M	$29.82M	-$34.00M

CRDF Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$109.00K	$121.00K	$120.00K	$243.00K	$41.00K
Research & Development	$10.48M	$11.58M	$8.20M	$5.08M	$6.76M
Selling, General & Admin	$4.01M	$3.32M	$3.90M	$3.00M	$6.13M
Operating Expenses	$14.49M	$14.90M	$12.09M	$8.07M	$12.89M
Operating Income	-$14.38M	-$14.78M	-$11.97M	-$7.83M	-$12.85M
EBITDA	-$14.15M	-$14.78M	-$11.48M	-$7.60M	-$12.63M
Pretax Income	-$13.43M	-$13.94M	-$11.26M	-$7.22M	-$12.35M
Net Income	-$13.43M	-$13.94M	-$11.26M	-$7.22M	-$12.35M
Diluted EPS	-0.20	-0.21	-0.17	—	-0.18
Diluted Shares	66.52M	66.53M	66.88M	—	68.35M

CRDF Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$24.09M	$10.78M	$10.13M	$17.47M	$8.54M
Receivables	$405.00K	$526.00K	$254.00K	$182.00K	$191.00K
Current Assets	$82.71M	$73.70M	$61.80M	$60.13M	$47.34M
Total Assets	$84.81M	$75.74M	$63.78M	$61.88M	$49.17M
Current Liabilities	$13.29M	$16.67M	$14.71M	$16.39M	$14.46M
Total Debt	$1.36M	$1.19M	$1.01M	$832.00K	$646.00K
Total Liabilities	$13.93M	$17.13M	$14.99M	$16.50M	$14.46M
Retained Earnings	-$397.61M	-$411.56M	-$422.81M	-$430.03M	-$442.38M
Shareholders' Equity	$70.88M	$58.61M	$48.79M	$45.39M	$34.71M
Working Capital	$69.42M	$57.03M	$47.09M	$43.73M	$32.88M

CRDF Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$12.79M	-$8.33M	-$10.83M	-$5.97M	-$12.29M
Capital Expenditure	—	—	-$18.00K	—	—
Free Cash Flow	-$12.79M	-$8.35M	-$10.85M	-$5.97M	-$12.29M
Depreciation & Amortisation	$228.00K	-$41.00K	$494.00K	$223.00K	$221.00K
Stock-Based Compensation	$1.36M	$1.68M	$1.38M	$1.26M	$1.66M
Investing Cash Flow	-$14.58M	-$4.98M	$10.16M	$10.75M	$3.26M
Financing Cash Flow	$3.00K	$0.00	$25.00K	$2.55M	$105.00K
Net Change in Cash	-$27.38M	-$13.31M	-$649.00K	$7.33M	-$8.93M

Market Snapshot

About

Cardiff Oncology, Inc. is a clinical-stage biotechnology company developing novel therapies for the treatment of cancer. Headquartered in San Diego, California, the company's lead product candidate is onvansertib, a Polo-like Kinase 1 (PLK1) inhibitor being evaluated in combination with standard-of-care chemotherapy across multiple cancer types. Cardiff is conducting clinical trials in colorectal cancer, KRAS-mutated metastatic colorectal cancer, and other solid tumors. The company's research focuses on targeting cancer cell proliferation and resistance mechanisms.